Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies

Article English OPEN
Gittelman, Marc; Marks,Leonard S.; Hill,Lawrence A.; Volinn,Weining; Hoel,Gary;
  • Publisher: Dove Press
  • Journal: Research and Reports in Urology,volume 3,pages1-5 (issn: 2253-2447, eissn: 1179-1551)
  • Related identifiers: doi: 10.2147/OAJU.S15333, doi: 10.2147/RRU.S15333, pmc: PMC3818930
  • Subject: symptoms | α1A-adrenoceptor antagonist | Original Research | Research and Reports in Urology | BPH | silodosin | rapid onset

Marc C Gittelman1, Leonard S Marks2, Lawrence A Hill3, Weining Volinn3, Gary Hoel31South Florida Medical Research, Aventura, Florida, USA; 2University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, California, USA; 3Watson Laborat... View more
  • References (15)
    15 references, page 1 of 2

    1. Marshall I, Burt RP, Chapple CR. Noradrenaline contractions of human prostate mediated by α1A-(α1C-) adrenoceptor subtype. Br J Pharmacol. 1995;115:781-786.

    2. Schwinn DA, Roehrborn CG. α1-Adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15:193-199.

    3. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007;9:181-190.

    4. Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994;113:723-728.

    5. Rudner XL, Berkowitz DE, Booth JV, et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation. 1999;100:2336-2343.

    6. Shibata K, Foglar R, Horie K, et al. KMD-3213, a novel, potent, α1Aadrenoceptor-selective antagonist: characterization using recombinant human α1-adrenoceptors and native tissues. Mol Pharmacol. 1995; 48:250-258.

    7. Yamada S, Okura T, Kimura R. In vivo demonstration of α1Aadrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther. 2001;296:160-167.

    8. Murata S, Taniguchi T, Takahashi M, Okada K, Akiyama K, Muramatsu I. Tissue selectivity of KMD-3213, an α1-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 2000; 164:578-583.

    9. Yamagishi R, Akiyama K, Nakamura S, et al. Effect of KMD3213, an α1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol. 1996;315:73-79.

    10. Akiyama K, Hora M, Tatemichi S, et al. KMD-3213, a uroselective and long-acting α1A-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther. 1999;291:81-91.

  • Similar Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark